| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* Division of Rheumatology, Tufts-New England Medical Center and Departments of Pathology and Family Medicine & Community Health, Tufts University School of Medicine, Boston, MA 02111
We have proposed that EBV uses mature B cell biology to access memory B cells as a site of persistent infection. A central feature of this model is that EBV adapts its gene expression profile to the state of the B cell it resides in and that the level of infection is stable over time. This led us to question whether changes in the behavior or regulation of mature B cells would alter the state of EBV persistence. To investigate this, we studied the impact of systemic lupus erythematosus (SLE), a disease characterized by immune dysfunction, on EBV infection. We show that patients with SLE have abnormally high frequencies of EBV-infected cells in their blood, and this is associated with the occurrence of SLE disease flares. Although patients with SLE have frequencies of infected cells comparable to those seen in immunosuppressed patients, in SLE the effect was independent of immunosuppressive therapy. Aberrant expression of viral lytic (BZLF1) and latency (latency membrane proteins 1 and 2a) genes was also detected in the blood of SLE patients. We conclude that the abnormal regulation of EBV infection in SLE patients reflects the sensitivity of the virus to perturbation of the immune system.
Related articles in The JI:
This article has been cited by other articles:
|
|
 |
|
  R. Takahashi, Y. Kano, Y. Yamazaki, M. Kimishima, Y. Mizukawa, and T. Shiohara Defective Regulatory T Cells In Patients with Severe Drug Eruptions: Timing of the Dysfunction Is Associated with the Pathological Phenotype and Outcome J. Immunol., June 15, 2009; 182(12): 8071 - 8079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Heyneman Systemic Lupus Erythematosus: A Therapeutic Update Journal of Pharmacy Practice, February 1, 2009; 22(1): 29 - 52. [Abstract] [PDF]
|
|
|
|
 |
|
 J.L. Casey, A.M. Coley, K. Parisi, and M. Foley Peptide mimics selected from immune sera using phage display technology can replace native antigens in the diagnosis of Epstein-Barr virus infection Protein Eng. Des. Sel., February 1, 2009; 22(2): 85 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Lunemann, O. Frey, T. Eidner, M. Baier, S. Roberts, J. Sashihara, R. Volkmer, J. I. Cohen, G. Hein, T. Kamradt, et al. Increased Frequency of EBV-Specific Effector Memory CD8+ T Cells Correlates with Higher Viral Load in Rheumatoid Arthritis J. Immunol., July 15, 2008; 181(2): 991 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Serafini, B. Rosicarelli, D. Franciotta, R. Magliozzi, R. Reynolds, P. Cinque, L. Andreoni, P. Trivedi, M. Salvetti, A. Faggioni, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain J. Exp. Med., November 26, 2007; 204(12): 2899 - 2912. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Lunemann, T. Kamradt, R. Martin, and C. Munz Epstein-Barr Virus: Environmental Trigger of Multiple Sclerosis? J. Virol., July 1, 2007; 81(13): 6777 - 6784. [Full Text] [PDF]
|
|
|
|
 |
|
 J J-Y Lu, D-Y Chen, C-W Hsieh, J-L Lan, F-J Lin, and S-H Lin Association of Epstein-Barr virus infection with systemic lupus erythematosus in Taiwan Lupus, March 1, 2007; 16(3): 168 - 175. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Dong, Y. Masaki, T. Takegami, T. Kawanami, K. Itoh, Z.-X. Jin, C.-R. Huang, X.-P. Tong, T. Fukushima, M. Tanaka, et al. Cloning and expression of two human recombinant monoclonal Fab fragments specific for EBV viral capsid antigen Int. Immunol., March 1, 2007; 19(3): 331 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Pegtel, A. Subramanian, D. Meritt, C.-H. Tsai, T.-S. Sheen, T. R. Golub, and D. A. Thorley-Lawson IFN-{alpha}-Stimulated Genes and Epstein-Barr Virus Gene Expression Distinguish WHO Type II and III Nasopharyngeal Carcinomas Cancer Res., January 15, 2007; 67(2): 474 - 481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J B Harley, I T W Harley, J M Guthridge, and J A James The curiously suspicious: a role for Epstein-Barr virus in lupus Lupus, November 1, 2006; 15(11): 768 - 777. [Abstract] [PDF]
|
|
|
|
|
|
H. Wang, M. W. Nicholas, K. L. Conway, P. Sen, R. Diz, R. M. Tisch, and S. H. Clarke EBV Latent Membrane Protein 2A Induces Autoreactive B Cell Activation and TLR Hypersensitivity. J. Immunol., September 1, 2006; 177(5): 2793 - 2802. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Lunemann, N. Edwards, P. A. Muraro, S. Hayashi, J. I. Cohen, C. Munz, and R. Martin Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis Brain, June 1, 2006; 129(6): 1493 - 1506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Dreyfus, A. J. Gross, and D. Thorley-Lawson Role of T Cells in EBV-Infected Systemic Lupus Erythematosus Patients J. Immunol., September 15, 2005; 175(6): 3460 - 3461. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
